The European Union have granted official approval for pharmaceutical company Novartis to market their diabetes drug Galvus for the treatment of type 2 diabetics . The decision is different to that made by the American Food and Drug Administratio, who have asked the firm for more data.
Galvus is a once daily oral agent to treat type 2 diabetes. The FDA called for further clinical trials to establish how effective the drug really is. The company are understood to be in ongoing negotiation with the FDA.
Novartis believe that Galvus could become a blockbuster drug, earning them revenue of over $1 billion per annum. Currently, due to the FDA decisio, the main rival to Galvus has a decent head-start. Although the two drugs were once expected to come to market at the same time, Januvia by Merck has been selling for some time.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…